AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05200182 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Electro gastrogram
Description: Volunteers will also be equipped with an MRI-compatible electro-gastrogram device to correlate gastric signals with brain activity during rsMRI acquisition.
Study NCT05200182 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electro gastrogram
Description: Volunteers will also be equipped with an MRI-compatible electro-gastrogram device to correlate gastric signals with brain activity during rsMRI acquisition.
Study NCT05200182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electro gastrogram
Description: Volunteers will also be equipped with an MRI-compatible electro-gastrogram device to correlate gastric signals with brain activity during rsMRI acquisition.
Study NCT06465615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-education with dichoptic reading on tablet
Description: Intervention 25 min/day, 5 days a week for 6 weeks at home (125-minute weekly load), under the supervision of a parent, on a dichoptic reading application on a loaned digital tablet, wearing anaglyph glasses provided and the patient's optical correction (if applicable).~During the first half of treatment (first 3 weeks), dichoptic separation takes place at the word level, and during the second half of treatment (last 3 weeks), it takes place at the individual letter level to promote precise eye alignment. This shift from dichoptic separation at word level to letter level increases the difficulty of the task. The text is freely chosen by the child and parent from a bank of age-appropriate books.
Study NCT06465615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional orthoptic rehabilitation
Description: Conventional orthoptic rehabilitation consisting of 12 x 25-minute sessions twice a week over 6 weeks, carried out with an orthoptist from Montpellier University Hospital, combined with reinforcement exercises to be carried out at home for 15 minutes a day under parental supervision, 5 days a week (125-minute weekly load). This is the standard orthoptic treatment offered in France to patients with symptomatic convergence insufficiency, according to orthoptic procedures (10-15 sessions of the order of 20-25 minutes and 10-15 minutes of daily reinforcement exercises at home).
Study NCT05200182 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Emotional Stroop task
Description: an emotional Stroop task adapted to food and body image representation
Study NCT05200182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Stroop task
Description: an emotional Stroop task adapted to food and body image representation
Study NCT04764981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Essence oils
Description: Consists in olfactory training using essence oils
Study NCT05834114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mckenzie protocol
Description: In this group 20 participants will receive McKenzie protocol with conventional physical therapy. Participants will be asked to sit to treat extension deficit. The participant will be in a comfortable sitting position with a proper back support. Head is kept in forward facing without any up and done movement (10 to 15 times). Then, he restored the neutral sitting posture, and at the end of the range of motion (ROM), he' tuck in chin by pushing the chin with his fingers (10 to 15 times). Subsequently, the participant will be requested to return to the original position while the therapist one hand's forefinger placed alongside the participant's mandible (to stabilize the head at full retraction position), and the heel of the other hand placed on the first or second dorsal vertebra (to provide posterior-anterior force). The exercises then repeated five or six times in a Session. the session will be of 45 mins, 3 session per week.
Study NCT05834114 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rhythmic Stabilization technique
Description: In this group participants will receive Rhythmic stabilization, with Conventional physiotherapy treatment the flexion , extension exercises performed. During flexion pattern the experimenter stood at the right side of patient and used his tip of fingers at chin. The experimenter then put his left hand at anterior side of head to apply resistance. then extension pattern is resisted and asked patient to match my resistance. The experimenter provided resistance against right rotation and lateral flexion provided during the exercise in order to induce strong muscle contractions. 3 sessions of 45 minutes a week, over a period of 10 weeks.
Study NCT05127525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRX-101
Description: IRX-101 to prevent infectious endophthalmitis following intravitreal injection therapy (IVT)
Study NCT05127525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Providone-Iodine Betadine to prevent infectious endophthalmitis following intravitreal injection therapy (IVT)
Study NCT04793906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron supplement with a lunch meal containing beef
Description: Participants will consume a lunch meal containing beef with an iron supplement for 8 weeks.
Study NCT04793906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron supplement with a lunch meal containing plant-based alternative
Description: Participants will consume a lunch meal containing plant-based alternative with an iron supplement for 8 weeks.
Study NCT06273943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Tablets, for oral use.
Description: Participants randomly assigned to the cabotegravir arm will be instructed to take by mouth a single tablet of cabotegavir 30mg once daily for four weeks.
Study NCT06273943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Extended-Release Injectable Suspension, for intramuscular use.
Description: Participants will receive 600mg (3mL) CAB LA injections intramuscularly at Month 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24. The injections will be performed in the gluteal muscle by trained healthcare providers at study sites.
Study NCT06273943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil/Emtricitabine 300mg/200mg fixed-dose combination tablets, for oral use
Description: * Daily regimen: a single tablet of TDF/FTC every 24 hours, regardless of sexual activity. If PrEP was stopped, resume with two pills of TDF/FTC followed by one pill every 24 hours.~* On-demand regimen: a loading dose of two pills of TDF/FTC 2 to 24 hours before sexual intercourse, a third pill 24 hours after the first drug intake and a fourth pill 24 hours later. In case of daily sexual intercourse, participants will be instructed to take one pill per day until the last sexual intercourse, then to take the two post-exposure pills. If the last dose of TDF/FTC was taken less than one week prior, a leading dose with a single pill of TDF/FTC is sufficient.
Study NCT06273943 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectal Biopsies
Description: This intervention concerns only participants involved in the rectal tissue HIV-1 permissibility sub-study.~The proctologist collects ten rectal biopsies at different time points before and after PrEP initiation according to the randomization arm.
Study NCT06273943 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal Biopsies
Description: This intervention concerns only participants involved in the rectal tissue HIV-1 permissibility sub-study.~The proctologist collects ten rectal biopsies at different time points before and after PrEP initiation according to the randomization arm.
Study NCT05955365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor
Description: The choice of P2Y12 inhibitor is left at investigator's discretion.
Study NCT05955365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P2Y12 inhibitor
Description: The choice of P2Y12 inhibitor is left at investigator's discretion.
Study NCT05955365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin is administered for up to 1 month after PCI at investigator's discretion
Study NCT05955365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOAC
Description: The choice of DOAC is left at investigator's discretion.
Study NCT05955365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DOAC
Description: The choice of DOAC is left at investigator's discretion.
Study NCT05343819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AON-D21
Description: AON-D21 is a PEGylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
Study NCT05343819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isotonic glucose solution identical in appearance to AON-D21.
Study NCT05400226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGT-309
Description: VGT-309 is an tumor-targeted, activatable fluorescent imaging agent which will be used with near infrared imaging during surgery to identify tumor.
Study NCT05168956 — intervention group
Intervention type: OTHER
Intervention: Collect data of medical record
Description: Collect data of medical record:~* Genealogy characteristics~* Family characteristics: Number of members in the sibling, rank in the sibling / incestuous relationships or not~* Graphic representation: age / gender / age at time of sexual assault / whether or not a victim of sexual violence / education / family dynamics / living environment during childhood / Criminal category
Study NCT05218863 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05367973 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVR Dose 1
Description: Estradiol 80 ug/day + progesterone 4 mg/day
Study NCT05367973 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVR Dose 2
Description: Estradiol 160 ug/day + progesterone 8 mg/day
Study NCT04749641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Histone H3.3-K27M Neoantigen Vaccine Therapy
Description: The researched vaccine, containing H3.3-K27M-targeting neoantigen peptides and poly ICLC, will be administered through subcutaneous injection into DIPG patients after they complete surgical/stereotactic biopsy and conformal radiotherapy. The day of first vaccine injection is defined as D1 (day 1), and then the injections will be administered on D3, D15, Day 29, Day 57, Day 85 and one injection every 8 weeks thereafter. In order to determine the Maximum Tolerated Dose (MTD) of the vaccine, a 6+3 dose escalation design is applied. There are three doses for the vaccine. Dose 1: 0.5mg peptide + Poly ICLC; Dose 2: 1mg peptide + Poly ICLC; Dose 3: 2mg peptide + Poly ICLC.
Study NCT05924191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Intra-oral irradiations wll be performed with a low intensity Laser device at 4 anatomical points, with a wavelength of 660 nm. The extraoral FBM will be applied with 1 cluster (20cm2) with a wavelength of 630nm. Subsequently, the same region will be irradiated with the same cluster, using the 4 LEDs with a wavelength of 850 nm 1 hour before performing the surgery.
Study NCT05924191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Corticosteroid
Description: Participants will receive 1 hour before the surgery a placebo tablet, with the same physical and organoleptic characteristics, composed of corn starch, without harmful effects on health and simulating Dexamethasone (Celsius Laboratory, Montevideo, Uruguay).).
Study NCT05924191 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Simulation Photobiomodulation
Description: The irradiation simulations will be practiced in the same anatomical points described in the experimental group. This protocol will be carried out 1 hour before the surgical procedure (Baseline). The Laser device will be disconnected and its beep sound will be recorded and run on simulating the irradiation.
Study NCT05924191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: The patients will receive Dexamethasone 8 mg (Corodex, Laboratorio Celsius, Montevideo, Uruguay) PO 1 hour before surgery (Almeida et al 2019)
Study NCT06630364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: Induction: Sevoflurane in N2O/O2, Propofol (1-1.5 mg/kg) Analgesia: Ketamine (0.5 mg/kg) Maintenance: Sevoflurane
Study NCT06630364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl
Description: Induction: Sevoflurane in N2O/O2 Analgesia: Propofol (1-1.5 mg/kg), Fentanyl (1 µg/kg) Maintenance: Sevoflurane
Study NCT06478212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorasidenib
Description: To be taken by mouth once daily in 28-day cycles with no break between cycles
Study NCT06478212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: To be taken by mouth once daily for the first 5 days of each 28-day cycle, for a maximum of 12 cycles
Study NCT05634044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eNose Device
Description: Participants will place the e-Nose device in their bathroom to record VOCs from the ambient air after they have a bowel movement. In addition to this, all participants will complete 2 blood draws 3 stool collections and questionnaires over the course of 4 visits during a 3-week period.
Study NCT04876079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test to induce a decline in plasma glucose
Description: Participants will be admitted at the research center at 7:00 after an overnight fast. A venous catheter will be inserted into an arm vein for blood sampling purposes. A subcutaneous insulin bolus will be administered to bring plasma glucose to the glycemic threshold. Oral carbohydrates (16g) will be given when plasma glucose levels are at the target threshold. Sixty minutes after carbohydrates consumption, a standardized meal will be provided and participants will be discharged 90 minutes after the meal.
Study NCT04876079 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G6
Description: Participants will have to wear a Dexcom G6 during study interventions
Study NCT04833712 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radioablation
Description: Stereotactic Radioablation targets on the pulmonary vein ostium aiming to achieve PVI
Study NCT04876079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dex4
Description: When the glycemic threshold is reach, participants will be given 16g of Dex4
Study NCT04876079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: A subcutaneous insulin bolus will be given to induce a decline in plasma glucose and reach the glycemic threshold.
Study NCT05767684 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Vaccine
Description: Approximately 1.5 x 10\^6±20% cells will be subcutaneously injected to the patient's inguinal area (either left side or right side can be injected, only one area will be injected each time) on day 1, 8, 15, 29, 85, 141, 197, 253 and 309.
Study NCT05767684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 10mg/day on day 43-77
Study NCT05767684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3mg/kg on day 43, 57 and 71.
Study NCT04860518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN beta-1a
Description: Treated daily with IFN beta-1a 10 μg as an IV bolus for 6 days while hospitalised
Study NCT04860518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Treated daily with dexamethasone 6 mg as an IV bolus for 6 days while hospitalised
Study NCT05384028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse -led case management
Description: This study would apply case management to the whole course management of AMI patients from admission to 6 months after discharge. Pharmacists, nutritionists, rehabilitation specialists and psychiatrists led by nurse would take the initiative to conduct individualized assessment and health guidance, and case managers would participate in the whole process of inpatient diagnosis and treatment. Coordinating multidisciplinary medical resources to jointly implement diagnosis and treatment and rehabilitation for patients can improve the quality of care.
Study NCT05384028 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine inpatient care and post-discharge follow-up management
Description: Patients in the control group will receive routine inpatient care and post-discharge follow-up management
Study NCT05306366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]-Lu AF90103
Description: PET ligand administrated as a single intravenous bolus injection
Study NCT05921058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secretome
Description: Mesenchymal stem cell secretome obtained from Kalbe Pharma Company
Study NCT05921058 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl 0,9% infusion
Study NCT05383040 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous release
Description: Percutaneous release of A1 pulley release will be performed in the well-managed operation theater set up, using an 18 gauge hypodermic needle, after preparation of the skin and injection of 1ml 2% plain lidocaine. The proper location of the pulley will be defined using surface landmarks in each digit after waiting a few minutes to allow the anesthetic to take effect the 18 gauge needle will be longitudinally moved to keep the level of the needle parallel with the tendon grating sensation will be elucidated confirming the cut of pulley until there is no grating sensation felt and improvement of symptoms. A sterile dressing will be placed.
Study NCT04897698 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LB001
Description: Probiotics
Study NCT04897698 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: LB001
Description: Probiotics
Study NCT01594697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT04976283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone with (or without) metformin and/or DPP4 inhibitor (no SGLT2 inhibitor). The maximum dose for metformin would be 2.5 g/day, while for pioglitazone would be 45mg/day. The maximum dose for DPP4 inhibitor would be 100mg/day.
Study NCT04976283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Empagliflozin with (or without) metformin and/or DPP4 inhibitor (no pioglitazone). The maximum dose for metformin would be 2.5g/day, while for empagliflozin would be 25mg/day depending on follow up blood sugar levels and tolerability. The maximum dose 100mg daily.
Study NCT04976283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone + Empagliflozin
Description: Pioglitazone with (or without) metformin and/or DPP4 inhibitor, plus empagliflozin. The maximum dose for metformin would be 2.5g/day; for pioglitazone would be 45mg/day and 25mg/day for empagliflozin, and 100mg daily for DPP4 inhibitors (depending on follow up blood sugar levels and tolerability).
Study NCT06559098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile coordinated reset (vCR)
Description: Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain
Study NCT05944133 — intervention group
Intervention type: OTHER
Intervention: No intervention, observational retrospective study
Description: No intervention
Study NCT04052243 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Invasive exercise testing
Description: Invasive hemodynamic exercise testing
Study NCT05476627 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarkers
Description: Blood,urine and imaging biomarkers for early diagnosis and prediction of prognosis.
Study NCT05717049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline Tablets
Description: 12 week oral treatment
Study NCT06111885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indapamide 2.5 MG
Description: 1 indapamide 2.5 mg capsule per day for 28 days
Study NCT06111885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide 50Mg
Description: 1 hydrochlorothiazide 50 mg capsule per day for 28 days
Study NCT06111885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone 25mg
Description: 1 chlorthalidone 25 mg capsule per day for 28 days
Study NCT04683692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Cerebral MRI will be performed without gadolinium contrast using a 3 Tesla scanner prior to and 1 to 7 days after catheter ablation
Study NCT04683692 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: Cerebral MRI will be performed without gadolinium contrast using a 3 Tesla scanner prior to and 1 to 7 days after catheter ablation
Study NCT04683692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Testing
Description: Laboratory blood testing to include high sensitivity CRP (hs-CRP), interleukin-6 (IL-6), NT-proBNP and high sensitivity troponin prior to and post-ablation
Study NCT04683692 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Testing
Description: Laboratory blood testing to include high sensitivity CRP (hs-CRP), interleukin-6 (IL-6), NT-proBNP and high sensitivity troponin prior to and post-ablation
Study NCT04692792 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: consume 1 bottle (50 mL) per day for 8 weeks